ReviewJournal of cellular and molecular medicine
Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine.
Review in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed.
- Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis.Stem cell reviews and reports · 2012Trial
- Immunomodulatory effects of TAK-242 on osteogenesis of mesenchymal stem cells in acute inflammatory conditions.BMC molecular and cell biology · 2026Article
- Femtosecond label-free imaging evaluates the metabolism of mesenchymal stromal cells.Human cell · 2026Article
- CD44-Binding Peptide-Functionalized Antibiofouling Polymer Surface for High-Performance Separation of Human Mesenchymal Stromal Cells.Chembiochem : a European journal of chemical biology · 2026Article
- Fucoxanthin protects placenta-derived human mesenchymal stem cells against oxidative stress-induced apoptosis by modulating genes involved in DNA damage repair, ER stress response, p53-induced apoptosis.Stem cell research & therapy · 2025Article
- Microfluidics-Based Microcarriers for Live-Cell Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective.Archives of dermatological research · 2025Review
- "Remodeling the intestinal immune microenvironment": immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Precision Nanomedicine with Bio-Inspired Nanosystems: Recent Trends and Challenges in Mesenchymal Stem Cells Membrane-Coated Bioengineered Nanocarriers in Targeted Nanotherapeutics.Journal of xenobiotics · 2024Review
- Evaluation of bone marrow-derived mesenchymal stem cells with eggshell membrane for full-thickness wound healing in a rabbit model.Cell and tissue banking · 2024Article
- Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade.Bioactive materials · 2024Review
- In Vitro Enhanced Osteogenic Potential of Human Mesenchymal Stem Cells Seeded in a Poly (Lactic-Craniomaxillofacial trauma & reconstruction · 2024Review
- Vitamin C, doxycycline, and azithromycin (VDA) targeted changes in cellular senescence-related genes in human adipose-derived mesenchymal stem cells.Iranian journal of basic medical sciences · 2024Article
- Enhancing viability and angiogenic efficacy of mesenchymal stem cells via HSP90Bioengineering & translational medicine · 2023Article
- A Worldwide Analysis of Adipose-Derived Stem Cells and Stromal Vascular Fraction in Orthopedics: Current Evidence and Applications.Journal of clinical medicine · 2023Review
- The JNK-EGR1 signaling axis promotes TNF-α-induced endothelial differentiation of human mesenchymal stem cells via VEGFR2 expression.Cell death and differentiation · 2023Article
- HucMSC-Exo Promote Mucosal Healing in Experimental Colitis by Accelerating Intestinal Stem Cells and Epithelium Regeneration via Wnt Signaling Pathway.International journal of nanomedicine · 2023Article
- Neural stem cell research in Africa: current realities and future prospects.Biology open · 2022Review
- Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.International journal of molecular sciences · 2022Review
- Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs), adherent fibroblastoid cells, present in bone marrow and many other tissues can be easily isolated and expanded in vitro. They are capable of differentiating into different cell types such as osteoblasts, chondrocytes, adipocytes, cardiomyocytes, hepatocytes, endothelial cells and neuronal cells. Such immense plasticity coupled with their ability to modulate the activity of immune cells makes them attractive for stem cell-based therapy aimed at treating previously incurable disorders. Preclinical studies have reported successful use of MSCs for delivering therapeutic proteins and repairing defects in a variety of disease models. These studies highlighted the in vivo potential of MSCs and their ability to home to injury sites and modify the microenvironment by secreting paracrine factors to augment tissue repair. Their therapeutic applicability has been widened by genetic modification to enhance differentiation and tissue targeting, and use in tissue engineering. Clinical trials for diseases such as osteogenesis imperfecta, graft-versus-host disease and myocardial infarction have shown some promise, demonstrating the safe use of both allogeneic and autologous cells. However, lack of knowledge of MSC behaviour and responses in vitro and in vivo force the need for basic and animal studies before heading to the clinic. Contrasting reports on immunomodulatory functions and tumorigenicity along with issues such as mode of cell delivery, lack of specific marker, low survival and engraftment require urgent attention to harness the potential of MSC-based therapy in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.